Conditions: Head and Neck Cancer
Keywords: Head and Neck Cancer Thrombospondin Analogue ABT-510 Antiangiogenic agent Lung Skin Thyroid
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
The goals of this clinical research study are to see how individuals with advanced head and neck cancer respond to treatment with the new drug thrombospondin (ABT-510) and to learn how effective it is in destroying cancer cells. The safety of ABT-510 and the effect ABT-510 has on cells in the body will also be studied.

Detailed description:
This is a phase Ib/II, single-center, open-label study designed to assess the safety, tolerability, pharmacokinetics, and biologic efficacy of ABT-510 (thrombospondin). Participants will be patients with incurable head and neck cancer.

Patients will begin at a fixed dose level of thrombospondin subcutaneously twice daily. Cycles of treatment are 28 days (4 weeks). Patients will be treated with thrombospondin until progression of tumor or toxicity.

Arms:
arm 1: Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.

Interventions: intervention 1: ABT-510
Intervention descriptions: intervention 1: 100 mg subcutaneously twice daily

Protocol document: